RESUMO
Monoclonal gammopathy of undetermined significance (MGUS) has been associated with an increased risk of thrombosis. We carried out a retrospective multicentre cohort study on 1491 patients with MGUS. In 49 patients (3.3%) MGUS was diagnosed after a thrombotic event. Follow-up details for a period of at least 12 months after diagnosis of MGUS were obtained in 1238 patients who had no recent history of thrombosis (<2 years) prior to diagnosis, for a total of 7334 years. During the follow-up, 33 of 1238 patients (2.7%) experienced thrombosis, with an incidence of 2.5 arterial events and 1.9 venous events per 1000 patient-years. Multivariate analysis showed increased risks of arterial thrombosis in patients with cardiovascular risk factors [hazard ratio (HR) 4.92, 95%confidence interval (CI) 1.42-17.04], and of venous thrombosis in patients with a serum monoclonal (M)-protein level >16 g/l at diagnosis (HR 3.08, 95%CI 1.01-9.36). No thrombosis was recorded in patients who developed multiple myeloma (n = 50) or other neoplastic diseases (n = 21). The incidence of arterial or venous thrombosis in patients with MGUS did not increase relative to that reported in the general population for similarly aged members. Finally, the risk of venous thrombosis did increase when the M-protein concentration exceeded >16 g/l.
Assuntos
Gamopatia Monoclonal de Significância Indeterminada/complicações , Trombofilia/etiologia , Trombose/epidemiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Arteriopatias Oclusivas/epidemiologia , Arteriopatias Oclusivas/etiologia , Fibrilação Atrial/epidemiologia , Complicações do Diabetes/epidemiologia , Progressão da Doença , Dislipidemias/epidemiologia , Feminino , Seguimentos , Humanos , Hipertensão/epidemiologia , Incidência , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/sangue , Mieloma Múltiplo/epidemiologia , Proteínas do Mieloma/análise , Isquemia Miocárdica/epidemiologia , Isquemia Miocárdica/etiologia , Neoplasias/epidemiologia , Estudos Retrospectivos , Fatores de Risco , Fumar/epidemiologia , Acidente Vascular Cerebral/epidemiologia , Acidente Vascular Cerebral/etiologia , Trombose/etiologia , Trombose Venosa/epidemiologia , Trombose Venosa/etiologia , Adulto JovemRESUMO
UNLABELLED: The aim of the present study waw to assess efficacy and safety of radio-immunotherapy with Zevalin (RIT-Z) in heavily pre-treated, rituximab-refractory patients. PATIENTS AND METHODS: We studied 12 patients with indolent lymphoma and 7 with aggressive lymphoma. The median number of prior rituximab-containing treatments was 2; overall, 3 therapies had been previously given. Ten patients received RIT-Z as salvage therapy, 9 at high risk of relapse received RIT-Z as consolidation. Staging and follow-up were obtained by positron-emission tomography. Outcomes assessed were failure-free survival (FFS) and time to next treatment (TTNT). RESULTS: Overall FFS and TTNT were 5 and 11 months, respectively; median follow-up 13 months. Major findings were i) no long-term remissions observed in 7 patients who had not responded to their most recent therapy and ii) lack of association between any pre-therapy variables analysed and outcomes. Different subgroups showed no difference in terms of toxicity. CONCLUSION: We encourage the use of RIT-Z as a consolidation for pre-treated patients with both indolent and aggressive lymphoma.
Assuntos
Anticorpos Monoclonais/administração & dosagem , Linfoma Folicular/radioterapia , Linfoma Difuso de Grandes Células B/radioterapia , Radioimunoterapia/métodos , Radioisótopos de Ítrio/administração & dosagem , Adulto , Idoso , Anticorpos Monoclonais Murinos , Resistencia a Medicamentos Antineoplásicos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Radioimunoterapia/efeitos adversos , Estudos Retrospectivos , RituximabRESUMO
The BEACOPP regimen is a consolidated first-line treatment regimen for advanced stage Hodgkin lymphoma (HL), while few data are available on the efficacy of this regimen in advanced disease. About 50% of patients with HL relapsed after or refractory to first-line therapy achieve a durable response after peripheral blood stem cell transplantation (PBSCT). Patients relapsing after a PBSCT (performed as second line therapy) have a very poor prognosis. We evaluated the efficacy of BEACOPP in two settings: patients refractory or in relapse after first-line therapy (Group A) and patients relapsing after a PBSCT (Group B). Twenty-three patients with HL, admitted between February 2003 and April 2007, were retrospectively studied: 10 patients in Group A and 13 in Group B. Group A: Nine complete remissions (CR) and one partial remission (PR) were achieved following BEACOPP treatment. After a median follow-up of 32 months, one patient has died due to secondary leukemia, while the other eight are alive, five (50%) in second CR, three in third CR after PBSCT and one with disease. Group B: Eight of the 13 patients (62%) obtained a CR, one patient a PR, two were refractory and two have died of toxicity. To date, eight patients (62%) are alive, four (31%) still in CR. All patients experienced hematologic toxicity (WHO 3-4) with two deaths due to septic shock. These results show that BEACOPP is an effective regimen for both refractory/relapsed patients with HL after first-line treatment (Group A) and for patients relapsing after a PBSCT (Group B) with a 3-year probability of overall survival, progression-free survival, and cumulative incidence of relapse of 90, 50, and 33.3% in Group A, and 61, 31, and 37.5% in Group B, respectively.